These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 33663259)

  • 21. Acute subjective effects in LSD- and MDMA-assisted psychotherapy.
    Schmid Y; Gasser P; Oehen P; Liechti ME
    J Psychopharmacol; 2021 Apr; 35(4):362-374. PubMed ID: 33853422
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of the Psychological Insight Questionnaire among a sample of people who have consumed psilocybin or LSD.
    Davis AK; Barrett FS; So S; Gukasyan N; Swift TC; Griffiths RR
    J Psychopharmacol; 2021 Apr; 35(4):437-446. PubMed ID: 33427007
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers.
    Johnson MW; Sewell RA; Griffiths RR
    Drug Alcohol Depend; 2012 Jun; 123(1-3):132-40. PubMed ID: 22129843
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Psilocybin occasioned mystical-type experiences.
    James E; Robertshaw TL; Hoskins M; Sessa B
    Hum Psychopharmacol; 2020 Sep; 35(5):e2742. PubMed ID: 32573835
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of varied doses of psilocybin on time interval reproduction in human subjects.
    Wackermann J; Wittmann M; Hasler F; Vollenweider FX
    Neurosci Lett; 2008 Apr; 435(1):51-5. PubMed ID: 18325673
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience.
    Pokorny T; Preller KH; Kraehenmann R; Vollenweider FX
    Eur Neuropsychopharmacol; 2016 Apr; 26(4):756-66. PubMed ID: 26875114
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness.
    MacLean KA; Johnson MW; Griffiths RR
    J Psychopharmacol; 2011 Nov; 25(11):1453-61. PubMed ID: 21956378
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Two dose investigation of the 5-HT-agonist psilocybin on relative and global cerebral blood flow.
    Lewis CR; Preller KH; Kraehenmann R; Michels L; Staempfli P; Vollenweider FX
    Neuroimage; 2017 Oct; 159():70-78. PubMed ID: 28711736
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risks and benefits of psilocybin use in people with bipolar disorder: An international web-based survey on experiences of 'magic mushroom' consumption.
    Morton E; Sakai K; Ashtari A; Pleet M; Michalak EE; Woolley J
    J Psychopharmacol; 2023 Jan; 37(1):49-60. PubMed ID: 36515370
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Psilocybin-induced spiritual experiences and insightfulness are associated with synchronization of neuronal oscillations.
    Kometer M; Pokorny T; Seifritz E; Volleinweider FX
    Psychopharmacology (Berl); 2015 Oct; 232(19):3663-76. PubMed ID: 26231498
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Awe: a putative mechanism underlying the effects of classic psychedelic-assisted psychotherapy.
    Hendricks PS
    Int Rev Psychiatry; 2018 Aug; 30(4):331-342. PubMed ID: 30260256
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A qualitative report on the subjective experience of intravenous psilocybin administered in an FMRI environment.
    Turton S; Nutt DJ; Carhart-Harris RL
    Curr Drug Abuse Rev; 2014; 7(2):117-27. PubMed ID: 25563444
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction.
    Garcia-Romeu A; Griffiths RR; Johnson MW
    Curr Drug Abuse Rev; 2014; 7(3):157-64. PubMed ID: 25563443
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Health Benefits and Positive Acute Effects of Psilocybin Consumption: A Quantitative Textual Analysis of User Self-Reported Data.
    Bienemann B; Barbosa AR; Cruz LVMD; Multedo M; Mograbi D
    J Psychoactive Drugs; 2024; 56(3):324-332. PubMed ID: 37348116
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mystical and Other Alterations in Sense of Self: An Expanded Framework for Studying Nonordinary Experiences.
    Taves A
    Perspect Psychol Sci; 2020 May; 15(3):669-690. PubMed ID: 32053465
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors.
    Griffiths RR; Johnson MW; Richards WA; Richards BD; Jesse R; MacLean KA; Barrett FS; Cosimano MP; Klinedinst MA
    J Psychopharmacol; 2018 Jan; 32(1):49-69. PubMed ID: 29020861
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The 5-HT2A/1A agonist psilocybin disrupts modal object completion associated with visual hallucinations.
    Kometer M; Cahn BR; Andel D; Carter OL; Vollenweider FX
    Biol Psychiatry; 2011 Mar; 69(5):399-406. PubMed ID: 21126732
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factor Analysis of the Mystical Experience Questionnaire: A Study of Experiences Occasioned by the Hallucinogen Psilocybin.
    Maclean KA; Leoutsakos JM; Johnson MW; Griffiths RR
    J Sci Study Relig; 2012 Dec; 51(4):721-737. PubMed ID: 23316089
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neural and subjective effects of inhaled N,N-dimethyltryptamine in natural settings.
    Pallavicini C; Cavanna F; Zamberlan F; de la Fuente LA; Ilksoy Y; Perl YS; Arias M; Romero C; Carhart-Harris R; Timmermann C; Tagliazucchi E
    J Psychopharmacol; 2021 Apr; 35(4):406-420. PubMed ID: 33567945
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up.
    Gukasyan N; Davis AK; Barrett FS; Cosimano MP; Sepeda ND; Johnson MW; Griffiths RR
    J Psychopharmacol; 2022 Feb; 36(2):151-158. PubMed ID: 35166158
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.